Your browser is no longer supported. Please, upgrade your browser.
ATHX Athersys, Inc. monthly Stock Chart
Athersys, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own2.10% Shs Outstand197.34M Perf Week-3.66%
Market Cap295.19M Forward P/E- EPS next Y-0.41 Insider Trans2.35% Shs Float178.74M Perf Month-6.51%
Income-66.50M PEG- EPS next Q-0.12 Inst Own29.00% Short Float15.60% Perf Quarter-27.02%
Sales0.50M P/S590.38 EPS this Y-65.40% Inst Trans-0.49% Short Ratio15.50 Perf Half Y-43.17%
Book/sh0.22 P/B7.18 EPS next Y2.40% ROA-112.70% Target Price- Perf Year17.91%
Cash/sh0.33 P/C4.78 EPS next 5Y- ROE-176.60% 52W Range1.13 - 4.38 Perf YTD28.46%
Dividend- P/FCF- EPS past 5Y-0.50% ROI- 52W High-63.93% Beta-1.68
Dividend %- Quick Ratio3.30 Sales past 5Y28.30% Gross Margin- 52W Low39.82% ATR0.13
Employees83 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)38.83 Volatility6.99% 8.23%
OptionableYes Debt/Eq0.00 EPS Q/Q-45.60% Profit Margin- Rel Volume2.10 Prev Close1.56
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume1.80M Price1.58
Recom1.70 SMA20-9.43% SMA50-14.55% SMA200-29.71% Volume3,766,843 Change1.28%
Jun-25-20Initiated BofA/Merrill Buy $5
Aug-26-19Initiated Dawson James Buy $11
Feb-13-18Reiterated Maxim Group Buy $12 → $6
Aug-10-17Reiterated Maxim Group Buy $9 → $12
Feb-07-17Initiated Needham Buy $7
Mar-11-16Reiterated Maxim Group Buy $5 → $10
Jul-09-15Downgrade Piper Jaffray Overweight → Neutral
Jan-23-15Reiterated Maxim Group Buy $7 → $9
Apr-28-14Reiterated Maxim Group Buy $10 → $7
Dec-19-13Reiterated Maxim Group Buy $6 → $10
Oct-05-12Reiterated Maxim Group Buy $3 → $6
May-31-12Initiated Maxim Group Buy $3
Sep-13-10Reiterated WBB Securities Strong Buy $8 → $9
Jul-30-10Upgrade WBB Securities Buy → Strong Buy $8
Apr-12-10Initiated Brean Murray Buy $8
Nov-11-08Reiterated Leerink Swann Outperform $8 → $4
Sep-17-08Initiated Leerink Swann Outperform $8
Aug-01-08Initiated Canaccord Adams Buy $6
Jun-19-08Initiated Lazard Capital Buy $7
Jun-02-08Initiated Cowen & Co Outperform
Nov-16-20 06:00AM  
Nov-14-20 07:39AM  
Nov-11-20 06:00PM  
Nov-09-20 04:05PM  
Nov-05-20 06:05AM  
Oct-08-20 01:17PM  
Sep-29-20 08:53AM  
Sep-24-20 01:29PM  
Sep-23-20 09:57AM  
Aug-11-20 02:00AM  
Aug-10-20 04:00PM  
Aug-07-20 08:58AM  
Jul-20-20 02:00PM  
Jun-25-20 10:10AM  
Jun-22-20 02:54PM  
Jun-12-20 08:47AM  
Jun-09-20 05:41PM  
Jun-02-20 01:45PM  
May-18-20 06:00AM  
May-09-20 10:01PM  
May-07-20 04:05PM  
May-06-20 02:32PM  
May-05-20 06:00AM  
May-04-20 11:19AM  
May-01-20 06:00AM  
Apr-29-20 02:47PM  
Apr-28-20 06:40AM  
Apr-22-20 12:00AM  
Apr-21-20 08:00AM  
Apr-20-20 04:05PM  
Apr-15-20 09:33PM  
Apr-14-20 08:37AM  
Apr-13-20 09:54AM  
Mar-30-20 06:00AM  
Mar-26-20 10:15AM  
Mar-19-20 06:00AM  
Mar-16-20 04:05PM  
Mar-09-20 09:58AM  
Feb-10-20 08:00AM  
Feb-03-20 06:00AM  
Jan-24-20 05:36AM  
Jan-15-20 08:22AM  
Jan-14-20 06:00AM  
Dec-19-19 04:56PM  
Nov-25-19 11:22PM  
Nov-14-19 06:00AM  
Nov-11-19 09:30AM  
Nov-06-19 04:05PM  
Nov-03-19 07:47AM  
Oct-14-19 01:00PM  
Sep-25-19 08:00AM  
Sep-19-19 08:37AM  
Sep-05-19 11:22AM  
Aug-08-19 11:23AM  
Aug-07-19 04:05PM  
Jul-31-19 02:32PM  
Jul-08-19 11:00AM  
Jun-20-19 09:58AM  
Jun-13-19 08:01AM  
Jun-04-19 06:00AM  
May-28-19 06:00AM  
May-24-19 01:46PM  
May-20-19 12:15PM  
May-18-19 09:50AM  
May-14-19 03:54PM  
May-09-19 11:23AM  
May-08-19 04:05PM  
Apr-23-19 04:08PM  
Apr-15-19 10:00AM  
Apr-10-19 02:00PM  
Mar-20-19 08:08AM  
Mar-19-19 12:03PM  
Mar-14-19 07:16PM  
Mar-07-19 08:57AM  
Feb-27-19 11:04AM  
Feb-14-19 08:00AM  
Jan-24-19 02:20PM  
Jan-23-19 09:27AM  
Dec-17-18 06:00AM  
Dec-03-18 12:18PM  
Nov-13-18 12:29PM  
Nov-06-18 04:05PM  
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lehmann William JRPresident and COOSep 18Sale2.0420,00040,764490,525Sep 18 05:30 PM
Harrington John JExec Vice Pres and CSOSep 16Sale2.155,00010,761777,718Sep 17 06:16 PM
Harrington John JExec Vice Pres and CSOSep 15Sale2.215,00011,033782,718Sep 17 06:16 PM
TRAUB KENNETH HDirectorJun 24Buy2.2250,000110,900235,093Jun 24 05:09 PM
TRAUB KENNETH HDirectorJun 23Buy2.3150,000115,600185,093Jun 24 05:09 PM
TRAUB KENNETH HDirectorJun 22Buy2.4040,00096,000135,093Jun 24 05:09 PM
Lehmann William JRPresident and COOJun 18Sale2.8620,00057,176524,053Jun 18 08:42 PM
Campbell Laura KSenior Vice Pres FinanceApr 01Sale3.81137,894525,395371,628Apr 01 06:01 PM
Campbell Laura KSenior Vice Pres FinanceMar 31Sale2.9051,483149,357509,522Apr 01 06:01 PM
Campbell Laura KSenior Vice Pres FinanceMar 30Sale2.4044,929107,834561,005Apr 01 06:01 PM
Lehmann William JRPresident and COOMar 18Sale1.3930,00041,679425,645Mar 18 05:12 PM
Harrington John JExec Vice Pres and CSOMar 17Sale1.325,0006,586688,220Mar 18 04:26 PM
Harrington John JExec Vice Pres and CSOMar 16Sale1.255,0006,254693,220Mar 18 04:26 PM
Lehmann William JRPresident and COODec 18Sale1.1730,00035,202469,636Dec 18 05:22 PM
Harrington John JExec Vice Pres and CSODec 17Sale1.225,0006,103715,060Dec 18 04:46 PM
Harrington John JExec Vice Pres and CSODec 16Sale1.245,0006,185720,060Dec 18 04:46 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.